NCT03205046 - A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

November 20, 2019

Study Completion Date

November 20, 2019

Conditions

DLBCLRichter Syndrome

Interventions

DRUG

acalabrutinib

Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.

DRUG

vistusertib

Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase

Trial Locations (11)

Research Site, Bethesda

Research Site, Nashville

Research Site, Rochester

Research Site, Fairway

Research Site, Omaha

Research Site, Seattle

Research Site, Hackensack

Research Site, Headington

Research Site, London

Research Site, Nottingham

Research Site, Sutton